Supernus Pharmaceuticals, Inc. (SUPN)
56.92
+3.62
(+6.79%)
USD |
NASDAQ |
Feb 25, 15:52
Supernus Pharmaceuticals EPS Diluted (Quarterly) : -0.7978 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Biogen, Inc. | -0.3333 |
| Catalyst Pharmaceuticals, Inc. | 0.4153 |
| Oncotelic Therapeutics, Inc. | -0.0025 |
| Vertex Pharmaceuticals, Inc. | 4.651 |
| Krystal Biotech, Inc. | 1.699 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -45.12M |
| Revenue (Quarterly) | 192.10M |
| Total Expenses (Quarterly) | 237.22M |
| Enterprise Value | 2.817B |
| Gross Profit Margin (Quarterly) | 77.20% |
| Profit Margin (Quarterly) | -23.49% |
| Earnings Yield | -0.60% |
| Normalized Earnings Yield | -0.5095 |